Lipella Pharmaceuticals to Present at 2024 Spartan Capital Investor Conference
29 oct. 2024 08h30 HE
|
Lipella Pharmaceuticals Inc.
Lipella Pharmaceuticals to Present at 2024 Spartan Capital Investor Conference
Lipella Pharmaceuticals Announces U.S. Patent Allowance for Innovative Liposomal Drug Delivery Platform
15 oct. 2024 05h00 HE
|
Lipella Pharmaceuticals Inc.
Lipella Pharmaceuticals Announces U.S. Patent Allowance for Innovative Liposomal Drug Delivery Platform
Lipella Pharmaceuticals to Present at 2024 Maxim Healthcare Virtual Summit
09 oct. 2024 10h47 HE
|
Lipella Pharmaceuticals Inc.
PITTSBURGH, Oct. 09, 2024 (GLOBE NEWSWIRE) -- Lipella Pharmaceuticals, Inc. (Nasdaq: LIPO) (“Lipella” or the “Company”), a clinical-stage biotechnology company focused on addressing serious diseases...
Lipella Pharmaceuticals Reports Encouraging Early Tolerability Results in Phase 2a Trial of LP-310 for Oral Lichen Planus
24 sept. 2024 08h00 HE
|
Lipella Pharmaceuticals Inc.
Lipella Pharmaceuticals Reports Encouraging Early Tolerability Results in Phase 2a Trial of LP-310 for Oral Lichen Planus
Lipella Pharmaceuticals to Participate at H.C. Wainwright's 26th Annual Global Investment Conference in New York
27 août 2024 08h00 HE
|
Lipella Pharmaceuticals Inc.
Lipella Pharmaceuticals to Participate at H.C. Wainwright's 26th Annual Global Investment Conference in New York
Lipella Pharmaceuticals Launches Innovative Registry to Advance Oral Lichen Planus Research
22 août 2024 05h00 HE
|
Lipella Pharmaceuticals Inc.
Lipella Pharmaceuticals Launches Innovative Registry to Advance Oral Lichen Planus Research
Lipella Pharmaceuticals Unveils Advanced Bladder Imaging Technique at ICICJ Conference
21 août 2024 05h00 HE
|
Lipella Pharmaceuticals Inc.
Lipella Pharmaceuticals Unveils Advanced Bladder Imaging Technique at ICICJ Conference
Lipella Pharmaceuticals Doses First Two Patients in Phase 2a Oral Lichen Planus Clinical Trial
12 août 2024 05h00 HE
|
Lipella Pharmaceuticals Inc.
Lipella Pharmaceuticals Doses First Two Patients in Phase 2a Oral Lichen Planus Clinical Trial
Lipella Pharmaceuticals Announces Closing of $1.28 Million Registered Direct Offering of Common Stock Priced At-the-Market Under Nasdaq Rules
01 août 2024 16h05 HE
|
Lipella Pharmaceuticals Inc.
Lipella Pharmaceuticals Announces Closing of $1.28 Million Registered Direct Offering of Common Stock Priced At-the-Market Under Nasdaq Rules
Lipella Pharmaceuticals Announces $1.28 Million Registered Direct Offering of Common Stock Priced At-the-Market Under Nasdaq Rules
01 août 2024 08h00 HE
|
Lipella Pharmaceuticals Inc.
Lipella Pharmaceuticals Announces $1.28 Million Registered Direct Offering of Common Stock Priced At-the-Market Under Nasdaq Rules